Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

Insulin pump therapy ... which has been supported by Novo Nordisk, Medtronic, Roche Diagnostics, Boehringer Ingelheim, and Lilly through institutional research grants. R.W.H. has not received ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

As the leader of Connecticut’s #insulin4all chapter, I’ve met countless patients who have struggled to afford their insulin.

and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing heavily in another oral formulation: its next-generation GLP-1 analogue ...

The US Food and Drug Administration (FDA) has cleared the Omnipod 5 for use by people aged 18 and older with type 2 diabetes, a first for any automated insulin delivery (AID) system. The Omnipod 5 ...

They can also be paired with pumps to automate the insulin delivery ... some of Eli Lilly's and Novo Nordisk's insulin pens, and the Apple Watch. Glooko, a privately held company that provides ...